Clinical Study

A Prospective Phase II Trial Of Novottf-100A With Bevacizumab (Avastin) In Patients With Recurrent Glioblastoma

Posted Date: Mar 28, 2018

  • Investigator: Rekha Chaudhary
  • Specialties: Hematology/Oncology, Oncology, Neurosurgery, Cancer, Neurology
  • Type of Study: Drug

The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab naïve (meaning you have never received bevacizumab before) patients with recurrent GBM as measured by 6-month progression free survival.

Criteria:

To Be Eligible For This Study, Patients Must Have Been Diagnosed With A Brain Tumor Called Glioblastoma Or Other Grade Iv Malignant Glioma (I.E. Gliosarcoma, Small Cell Glioblastoma, Etc).

Keywords:

Cancer, Glioma, Brain Tumor, Cae3313, Brain

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.